Provectus Biopharmaceuticals’ Abstract on Liver Cancer Accepted for Poster Presentation at 6th Asia-Pacific Primary Liver C...
May 28 2015 - 3:01PM
Business Wire
Phase 1 Study Poster to be Presented in
Osaka, Japan, July 3, 2015 at 4:50 pm Local Time
APPLE Conference Runs July 3-5, 2015
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,
http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (“Provectus” or the “Company”), announced
today that the organizing committee of the 6th Asia-Pacific
Primary Liver Cancer Expert Meeting has accepted the Company’s
abstract "Phase 1 Study of PV-10 for Chemoablation of
Hepatocellular Cancer and Cancer Metastatic to the Liver", for a
poster presentation.
The presentation is scheduled for July 3, 2015, at 4:50-5:50 pm
local time. Making the presentation will be Dr. Sanjiv Agarwala,
chief of medical oncology and hematology at St. Luke’s Cancer
Center in Bethlehem, PA, and professor of medicine at Temple
University School of Medicine in Philadelphia. He served as the
principal investigator of the Phase I clinical trial that produced
the data being presented, as well as the principal investigator in
the Phase III clinical trial of PV-10 as a treatment for melanoma
which has just begun.
The conference runs July 3-5, 2015, and is being held at The
Hyatt Regency Osaka, in Osaka, Japan. The Company will post the
presentation on its website at www.pvct.com at the time of the
presentation. For more information on the conference, please visit
http://www2.convention.co.jp/apple2015/greeting/index.html.
Provectus will provide more details about the presentation and
conference as they become available.
About APPLE
APPLE 2015 is designed to promote exchanges of international and
regional expertise in the study and management of liver cancer. We
are very privileged to have a number of distinguished international
and local guest faculties who are prominent, world-class leaders in
this field, and have traveled a long way to share and discuss with
us the advances and challenges currently faced in the area of liver
cancer.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials, including its current phase 3 study in melanoma,
can be found at the NIH registry, www.clinicaltrials.gov. For
additional information about Provectus, please visit the Company’s
website at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as cancers of the liver, if such licensure is appropriate
considering the timing and structure of such a license, or to
commercialize PV-10 on our own to treat melanoma and other solid
tumors such as cancers of the liver;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150528006536/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon
Nurse, 212-564-4700DM, SVP – Investor RelationsorBill Gordon,
212-724-6312Media Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From May 2023 to May 2024